
A Setback for NHS Access – But Hope Remains Through Clinical Trials
This week’s decision by NICE (the National Institute for Health and Care Excellence) to reject funding for two groundbreaking Alzheimer’s drugs Leqembi™ (lecanemab) and Kisunla™ (donanemab) has […]